Drugs / difluoromethylornithine
difluoromethylornithine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03536728 | Jun 2018 → Dec 2022 | carcinoma | Aminex Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | difluoromethylornithine | “the use of difluoromethylornithine (DFMO) to block polyamine biosynthesis” PMID 40913836 ↗ Sep 2025 |
| Known as | DFMO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03536728 ↗ |
| Known as | DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate | “DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules” NCT03536728 ↗ |
| Action | Inhibit | “difluoromethylornithine (DFMO) to block polyamine biosynthesis” PMID 40913836 ↗ Sep 2025 |
| Route | Oral | “oral AMXT 1501 in combination with oral DFMO” PMID 40913836 ↗ Sep 2025 |